Greg Chopiuk

Statistics

Publications

Citations

851

H-Index

Active since

2006

Affiliations

Genomics Institute of the Novartis Research Foundation(Current)

Greg Chopiuk is an author at Genomics Institute of the Novartis Research Foundation specializing in oncology, tyrosine kinase inhibitors, and drug design.

Publications per year

2006–2015

Publications

Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials

Thomas H. Marsilje, Wei Pei, Bei Chen et al. · Journal of Medicinal Chemistry · 2013 · 412 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +16

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK

Anna Galkin, Jonathan S. Melnick, Sung Joon Kim et al. · Proceedings of the National Academy of Sciences · 2006 · 377 citations · Full text

Life Sciences, Oncology, Pharmacology +17

(R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors

Ha-Soon Choi, Paul V. Rucker, Zhicheng Wang et al. · ACS Medicinal Chemistry Letters · 2015 · 62 citations · Full text

Medicine, Oncology, Pharmacology +13

1–3 of 3